secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-08-24T12:30:08+00:00
Accession:  0001437749-26-028778
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia gets FDA confirmation of Helix catheter meeting minutes; De Novo submission planned this quarter
--------------------------------------------------------------------------------

- FDA confirmed final meeting minutes from May 2026 Pre-Submission Meeting on Helix Transendocardial Delivery Catheter System.
- BioCardia intends to submit follow-on pre-submission for Helix this quarter, incorporating agency advice.
- Successful De Novo clearance could enable independent Helix market clearance and enhance partnering for cell/gene/protein therapeutics.
- CEO Peter Altman stated the submission could enable Helix approval via De Novo pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926028778/0001437749-26-028778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926028778/bcda20260821_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-028778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer